<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01458054</url>
  </required_header>
  <id_info>
    <org_study_id>115711</org_study_id>
    <nct_id>NCT01458054</nct_id>
  </id_info>
  <brief_title>Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults</brief_title>
  <official_title>Phase 1, Open Label Study to Evaluate the Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase I open label drug interaction study to evaluate the effect of&#xD;
      omeprazole and ritonavir on GSK2336805.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase I open label drug interaction study with two objectives. The first&#xD;
      objective of this study (Cohort 1) is to determine if the pharmacokinetics of a single dose&#xD;
      of GSK2336805 are affected by co-administration with repeat doses of omeprazole, a&#xD;
      proton-pump inhibitor that is commonly used by chronic hepatitis C patients .&#xD;
&#xD;
      The second objective of this study (Cohort 2) is to determine if the pharmacokinetics of a&#xD;
      single dose of GSK2336805 are affected by co-administration with repeat doses of ritonavir, a&#xD;
      HIV protease inhibitor drug that is a potent inhibitor of CYP 3A4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2011</start_date>
  <completion_date type="Actual">November 28, 2011</completion_date>
  <primary_completion_date type="Actual">November 28, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the plasma concentration time curve from time zero to the last quantifiable time points</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>under the plasma concentration time curve from time zero to infinity</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration time curve from time zero to 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum observed concentration</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time to maximum observed concentration</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration at 24 hours post-dose</measure>
    <time_frame>24 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>last measureable concentration</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time of last measurable concentration</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>absorption lag time</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the elimination half-life</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent oral clearance</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent volume of distribution</measure>
    <time_frame>48 hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events</measure>
    <time_frame>24 hours</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects needing concurrent medications</measure>
    <time_frame>24 hours</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinical laboratory tests of clinical significance</measure>
    <time_frame>24 hours</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with electrocardiograms with clinically significant values</measure>
    <time_frame>24 hours</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with vital sign measures of clinical significance</measure>
    <time_frame>24 hours</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2336805 60mg x 1 dose (fasted) [Reference Treatment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omeprazole 40 mg q24h x 4 days (fed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2336805 60 mg x 1 dose and Omeprazole 40 mg on Day 1 (fasted) [Test Treatment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2336805 30mg x 1 dose (fasted) [Reference Treatment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ritonavir 100mg q12h x 4 days (fed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2336805 30 mg x 1 dose (fasted) and ritonavir 100mg q12h on Day 1 (fasted) [Test Treatment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ritonavir 100mg q12h x 1 day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)</intervention_name>
    <description>GSK2336805 and Omeprazole</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)</intervention_name>
    <description>GSK2336805 and Ritonavir</description>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_label>Treatment G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase&#xD;
             and bilirubin greater than or equal to 1.5x Upper Limit of Normal (ULN) (isolated&#xD;
             bilirubin greater than 1.5xULN is acceptable if bilirubin is fractionated and direct&#xD;
             bilirubin less than35%).&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameters&#xD;
             outside the reference range for the population being studied may be included only if&#xD;
             the Investigator and the GSK Medical Monitor agree that the finding is unlikely to&#xD;
             introduce additional risk factors and will not interfere with the study procedures.&#xD;
             Subjects with values outside the normal range should always be excluded from&#xD;
             enrollment.&#xD;
&#xD;
          -  Male or female between 18 and 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of:&#xD;
&#xD;
        Non-childbearing potential defined as pre-menopausal females with a documented tubal&#xD;
        ligation, oophorectomy, or hysterectomy; or postmenopausal defined as 12 months of&#xD;
        spontaneous amenorrhea&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use one of&#xD;
             the contraception methods listed in the protocol. This criterion must be followed from&#xD;
             the time of the first dose of study medication until the follow up visit.&#xD;
&#xD;
          -  Body weight greater than or equal to 50 kilograms for men and greater than or equal to&#xD;
             45 kilograms for women. Body mass index (BMI) between 18.5-32 inclusive will be&#xD;
             allowed (inclusive).&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  QTcB less than 450; or QTc less than 480 in subjects with Bundle Branch Block&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless in the opinion of the Investigator and GSK Medical&#xD;
             Monitor the medication will not interfere with the study procedures or compromise&#xD;
             subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 milliliters within a 56 day period.&#xD;
&#xD;
          -  Pregnant females as determined by positive serum or urine human chorionic gonadotropin&#xD;
             test at screening or prior to dosing.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  History or regular use of tobacco- or nicotine-containing products within 6 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or&#xD;
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior&#xD;
             to the first dose of study medication.&#xD;
&#xD;
          -  The subject's systolic blood pressure is outside the range of 90-140, or diastolic&#xD;
             blood pressure is outside the range of 45-90 or heart rate is outside the range of&#xD;
             50-100 beats per minute (bpm) for female subjects or 45-100 beats per minute for male&#xD;
             subjects.&#xD;
&#xD;
          -  Exclusion criteria for screening ECG (a single repeat is allowed for eligibility&#xD;
             determination):Heart rate less than 45 and greater than 100 bpm for men and less than&#xD;
             50 and greater than 100 bpm for women. PR interval less than 120 and greater than 220.&#xD;
             QRS duration less than 70 and greater than 120. QTc interval greater than 450.&#xD;
             Evidence of previous myocardial infarction (Does not include ST segment changes&#xD;
             associated with repolarization). Any conduction abnormality (including but not&#xD;
             specific to left or right complete bundle branch block, AV block [2nd degree or&#xD;
             higher], Wolf Parkinson White [WPW] syndrome). Sinus Pauses greater than 3 seconds.&#xD;
             Any significant arrhythmia which, in the opinion of the principal investigator and GSK&#xD;
             medical monitor, will interfere with the safety for the individual subject.&#xD;
             Non-sustained or sustained ventricular tachycardia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>October 6, 2011</study_first_submitted>
  <study_first_submitted_qc>October 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2011</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>omeprazole</keyword>
  <keyword>ritonavir</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

